US 12,492,241 B2
Broadly neutralizing antibodies against HIV
Mohammad Sajadi, Cockeysville, MD (US); George K. Lewis, Baltimore, MD (US); and Anthony DeVico, Alexandria, VA (US)
Assigned to University of Maryland, Baltimore, Baltimore, MD (US); and The United States Government as Represented by the Department of Veterans Affairs, Washington, DC (US)
Filed by University of Maryland, Baltimore, Baltimore, MD (US); and The United States Government as Represented by the Department of Veterans Affairs, Washington, D.C., DC (US)
Filed on May 9, 2023, as Appl. No. 18/314,490.
Application 18/314,490 is a continuation of application No. 16/725,596, filed on Dec. 23, 2019, granted, now 11,760,789.
Application 16/725,596 is a continuation of application No. PCT/US2018/039162, filed on Jun. 22, 2018.
Claims priority of provisional application 62/673,607, filed on May 18, 2018.
Claims priority of provisional application 62/591,244, filed on Nov. 28, 2017.
Claims priority of provisional application 62/589,614, filed on Nov. 22, 2017.
Claims priority of provisional application 62/573,764, filed on Oct. 18, 2017.
Claims priority of provisional application 62/523,437, filed on Jun. 22, 2017.
Prior Publication US 2024/0117018 A1, Apr. 11, 2024
Int. Cl. A61K 39/42 (2006.01); A61K 45/06 (2006.01); A61P 31/18 (2006.01); C07K 16/10 (2006.01)
CPC C07K 16/1063 (2013.01) [A61K 39/42 (2013.01); A61K 45/06 (2013.01); A61P 31/18 (2018.01); C07K 16/1045 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 7 Claims
OG exemplary drawing
 
1. One or more vectors comprising a nucleic acid encoding an anti-HIV antibody, wherein the anti-HIV antibody is selected from the group consisting of:
a. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYDFIDYV (SEQ ID NO:401), CDR H2 comprises MNPSGGGT (SEQ ID NO: 402) and CDR H3 comprises VRDRANGSGRRRFESVNWFLDL (SEQ ID NO:403); and a light chain variable region, wherein CDR L1 comprises HNY, CDR L2 comprises DEN and CDR L3 comprises WAFEN (SEQ ID NO:404);
b. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYRFPDYI (SEQ ID NO:497), CDR H2 comprises MNPMGGQV (SEQ ID NO: 421) and CDR H3 comprises VRDRSNGSGKRFESSNWFLDL (SEQ ID NO:441); and a light chain variable region, wherein CDR L1 comprises HNL, CDR L2 comprises DEN and CDR L3 comprises WAYEA (SEQ ID NO:408);
c. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYKFMDQL (SEQ ID NO:442), CDR H2 comprises MNPTYGQV (SEQ ID NO: 443) and CDR H3 comprises ARGPSGENYPFHY (SEQ ID NO:444); and a light chain variable region, wherein CDR L1 comprises RHII (SEQ ID NO:445), CDR L2 comprises DDD and CDR L3 comprises NTYEF (SEQ ID NO:446); and
d. an antibody comprising a heavy chain variable region, wherein CDR H1 comprises GYTFTDYL (SEQ ID NO:409), CDR H2 comprises MNPVYGQV (SEQ ID NO: 410) and CDR H3 comprises VRDTGDGSRRHFDSINWFLDL (SEQ ID NO:411); and a light chain variable region, wherein CDR L1 comprises HNY, CDR L2 comprises DFD and CDR L3 comprises WAFEA (SEQ ID NO:412).